An observational study in Acute Ischemic Stroke, Contrast-induced Nephropathy and Acute Kidney Injury, sponsored by Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Ischemic Stroke with a site in Turkey — 12 open to participants now, 16 under way, 1 of them phase 3. Ischemic Stroke · Turkey.
Among the 54 studies in Ischemic Stroke with a site in Turkey, this one has the largest enrollment of the 16 observational ones that give a count, is one of 8 that started in 2026, is one of 16 observational ones, and was the 50th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →12 of the 54 studies in Ischemic Stroke with a site in Turkey are open now. Recruiting first, the newest first:
Ankara Etlik City Hospital · Sites in Turkey
Ages 45+
Fenerbahce University · Sites in Turkey
Ages 18–80
Fenerbahce University · Sites in Turkey
Ages 18–80
RapidPulse, Inc · Sites in Turkey, United States, France and 1 more country
Ages 18–85
Akdeniz University · Sites in Turkey
Ages 45+ · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,760 is above the median of 300 across 776 observational studies indexed under Ischemic Stroke.
Median enrollment 50 across the 37 interventional studies, 90 across the 16 observational. Of the 34 that completed or were terminated, 3 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 54 have an industry lead sponsor. The 10 most frequent:
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital is the lead sponsor of 59 studies on the registry; 24 are open to participants now.
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital has 2 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
5 of the studies in Ischemic Stroke with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07453277Izmir Katip Celebi UniversityBlood-Based Molecular Clock Biomarkers Predict Acute Ischemic Stroke Onset: A Prospective Observational Study | 2027-03-01 |
| NCT07456956Fenerbahce UniversityHIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke | 2027-04-06 |
| NCT06029491RapidPulse, IncThrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions | 2027-06 |
| NCT06370182Anaconda Biomed S.L.Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter | 2027-08 |
| NCT07834333Ankara Etlik City HospitalEffectiveness of Theta Burst Stimulation For Upper and Lower Extremity Recovery in Stroke | 2027-08-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 54 studies in Ischemic Stroke with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the relationship between serum electrolyte levels and the development of contrast-induced acute kidney injury (CI-AKI) in patients with acute ischemic stroke undergoing endovascular therapy (EVT).
Contrast-induced nephropathy remains a significant complication associated with endovascular procedures and is linked to increased morbidity and mortality. While several risk factors have been identified, the role of serum electrolyte imbalances in the development of CI-AKI has not been fully elucidated.
In this retrospective cohort study, patients treated with EVT between 2018 and 2026 will be analyzed. Patients will be classified based on the presence or absence of CI-AKI according to changes in serum creatinine levels. Demographic data, comorbidities, laboratory parameters-including serum electrolytes-and procedural variables will be compared between groups.
The primary objective is to determine whether serum electrolyte levels are associated with the risk of CI-AKI. Secondary objectives include evaluating 90-day mortality and dialysis dependency in patients who develop CI-AKI.
This retrospective cohort study is designed to evaluate the association between serum electrolyte levels and the development of contrast-induced acute kidney injury (CI-AKI) in patients undergoing endovascular therapy (EVT) for acute ischemic stroke.
Endovascular treatment has become a standard of care for acute ischemic stroke; however, the use of iodinated contrast media carries a risk of nephrotoxicity. Contrast-induced acute kidney injury remains a clinically significant complication and is associated with prolonged hospitalization, increased healthcare costs, and higher mortality rates. Although several well-established risk factors for CI-AKI have been identified, including baseline renal dysfunction, diabetes mellitus, and contrast volume, the role of serum electrolyte imbalances has not been clearly defined.
Electrolyte disturbances may influence renal perfusion, tubular function, and systemic hemodynamics, potentially contributing to the pathophysiology of CI-AKI. Therefore, identifying electrolyte-related risk factors may help improve risk stratification and guide preventive strategies in high-risk populations.
In this study, patients who underwent EVT between 2018 and 2026 will be included. Prospectively collected clinical data will be analyzed retrospectively. Patients will be divided into two groups based on the development of CI-AKI, defined according to changes in serum creatinine levels following contrast exposure.
Comparative analyses will be performed between patients with and without CI-AKI to identify potential predictors. Multivariate regression analysis may be used to determine independent risk factors associated with CI-AKI development.
The findings of this study are expected to provide clinically relevant insights into the role of electrolyte balance in the development of CI-AKI and may contribute to improved peri-procedural risk assessment and patient management strategies in acute ischemic stroke populations undergoing endovascular therapy.
This study includes adult patients (≥18 years) with acute ischemic stroke who underwent endovascular therapy at a tertiary referral center between 2018 and 2026. Patients with sufficient clinical and laboratory data, including pre- and post-procedural serum creatinine measurements, will be eligible for inclusion.
The cohort reflects a real-world population of patients undergoing EVT, encompassing a wide range of demographic and clinical characteristics, including common vascular comorbidities. Patients will be stratified according to the development of contrast-induced acute kidney injury (CI-AKI) for comparative analyses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who developed contrast-induced acute kidney injury (CI-AKI) following endovascular therapy for acute ischemic stroke, defined by an increase in serum creatinine levels according to established diagnostic criteria after contrast exposure. These patients were identified based on post-procedural renal function changes and included in the analysis to evaluate clinical, laboratory, and procedural factors associated with CI-AKI development.
Other: No intervention (observational cohort study)
Patients who underwent endovascular therapy for acute ischemic stroke but did not develop contrast-induced acute kidney injury based on post-procedural serum creatinine measurements.
Other: No intervention (observational cohort study)
No experimental or therapeutic intervention was assigned. This observational retrospective cohort study evaluated patients undergoing endovascular therapy for acute ischemic stroke, who were subsequently categorized based on the presence or absence of contrast-induced acute kidney injury (CI-AKI). The study analyzed demographic, clinical, laboratory (including serum electrolyte levels) and procedural variables to identify potential risk factors associated with CI-AKI development.
Incidence of contrast-induced acute kidney injury (CI-AKI)
CI-AKI will be identified based on post-procedural serum creatinine changes after contrast exposure according to established diagnostic criteria.
Time frame: Within 48-72 hours after contrast exposure
90-day mortality
All-cause mortality occurring within 90 days after endovascular therapy in patients with and without contrast-induced acute kidney injury (CI-AKI).
Time frame: Within 90 days after endovascular therapy
Dialysis dependency in patients with CI-AKI
Requirement for renal replacement therapy (hemodialysis) within 90 days after endovascular therapy in patients who developed contrast-induced acute kidney injury (CI-AKI)
Time frame: Within 90 days after endovascular therapy
Change in serum creatinine
Change in serum creatinine levels from baseline to post-procedural measurements following contrast exposure.
Time frame: Baseline to 48-72 hours after endovascular therapy
Association between serum electrolyte levels and CI-AKI
Evaluation of the relationship between baseline serum electrolyte levels (sodium, potassium, chloride, calcium, magnesium, phosphate) and the development of contrast-induced acute kidney injury.
Time frame: Baseline (pre-procedural measurements)
Length of hospital stay
Total duration of hospitalization in days, compared between patients with and without CI-AKI.
Time frame: Within 90 days after endovascular therapy
Inflammatory markers and CI-AKI relationship
Association between inflammatory markers (e.g., C-reactive protein, procalcitonin) and the development of CI-AKI.
Time frame: Baseline (pre-procedural measurements)
Change in estimated glomerular filtration rate (eGFR)
Change in estimated glomerular filtration rate (eGFR) from baseline to post-procedural measurements following contrast exposure
Time frame: Baseline to 48-72 hours after endovascular therapy
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2026 to primary completion in Nov 2026, 6 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion May 2026 → Nov 2026 and completion May 2026 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital